Sleep More, Stress Less: 90-Day Trial of Neuralli Mood

Purpose

This decentralized, single-arm study evaluates the effects of 90 days of daily Neuralli Mood supplementation on perceived stress, sleep disturbance, mood, anxiety, depressive symptoms, happiness, and occupational burnout in adults experiencing stress or occasional sleep disruption. Participants serve as their own controls, completing validated self-report measures before beginning supplementation and again after the 90-day intervention, with safety and adherence check-ins during the study.

Conditions

  • Psychological Stress
  • Sleep Disturbance
  • Anxiety Symptoms
  • Depressive Symptoms
  • Occupational Burnout

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Age 18 years or older and able to provide informed consent. - Generally healthy adult experiencing stress, occasional sleep disruption, low mood, anxiety symptoms, or work-related burnout. - Willing and able to take two capsules of Neuralli Mood daily for 90 days. - Willing and able to complete electronic baseline, follow-up, adherence, and safety assessments. - Has reliable access to the internet and an email-enabled device.

Exclusion Criteria

  • Pregnant or nursing. - Known allergy or hypersensitivity to Neuralli Mood, probiotics, or any product ingredient. - Severe or unstable gastrointestinal disease, including a condition for which probiotic use may be inappropriate. - Immunocompromised status or current immunosuppressive therapy. - Severe or unstable mood disorder, acute psychiatric symptoms, or a current risk of harm to self or others. - A clinically significant sleep disorder for which participation or changes in symptoms should be managed by a healthcare professional. - Cognitive impairment or another condition that prevents informed consent or reliable completion of study procedures. - History of a severe allergic reaction when the investigator determines probiotic use may present an unacceptable risk. - Use of a medication or presence of a medical condition for which a healthcare professional advises against probiotic supplementation. - Any other circumstance that, in the investigator's judgment, makes participation inappropriate or unsafe.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
All participants complete baseline assessments, take two capsules of Neuralli Mood daily for 90 days, complete scheduled adherence and safety check-ins, and repeat the outcome assessments at the end of the supplementation period. Each participant serves as his or her own control.
Primary Purpose
Other
Masking
None (Open Label)
Masking Description
Participants and investigators know that Neuralli Mood is being administered. No placebo or blinded comparator is used.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Neuralli Mood Supplementation
Participants take two capsules of Neuralli Mood once daily, with or without food, at a consistent time for 90 days and complete scheduled study assessments and safety check-ins.
  • Dietary Supplement: Neuralli Mood
    Two acid-resistant capsules taken once daily for 90 days. Each daily dose contains 30 billion CFU of L. plantarum PS128 and 20 billion heat-treated cells of L. paracasei PS23. Other ingredients include microcrystalline cellulose, hypromellose, pectin, glycerol, silica, and magnesium stearate.
    Other names:
    • Bened Life Neuralli Mood

Recruiting Locations

Efforia - Decentralized United States Study
New York, New York 10003
Contact:
Matthew Amsden
help@efforia.com

More Details

Status
Recruiting
Sponsor
Efforia, Inc

Study Contact

Matthew Amsden
+13232844626
help@efforia.com

Detailed Description

Neuralli Mood is a probiotic and postbiotic dietary supplement containing the proprietary gut-brain strains L. plantarum PS128 and heat-treated L. paracasei PS23. Participants take two capsules once daily, with or without food, at a consistent time for 90 days. Each two-capsule daily dose contains 30 billion CFU of L. plantarum PS128 and 20 billion heat-treated cells of L. paracasei PS23. The study uses a prospective, open-label, single-group, within-participant design. Participants complete baseline assessments before the first dose and repeat the primary and secondary outcome assessments at the end of the 90-day supplementation period. Scheduled check-ins are used to assess adherence, tolerability, and adverse events. The study is exploratory and is intended to generate preliminary evidence and individualized before-and-after information. Results will be interpreted in light of the absence of a concurrent control group, participant self-selection, expectation effects, and reliance on self-reported outcomes.